Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 376 participants.

Also called NCT03386344

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 376 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03386344
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Mexico, New Zealand, Russia, South Korea, Taiwan (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03386344. Randomized; quadruple masking; primary purpose treatment. Start 2018-02-19 (actual); primary completion 2019-05-22 (actual). Results posted on 2021-06-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Acronym
SOTA-BONE
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sotagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Lexicon Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03386344
Content hash
1f02d73b09c3164f49eda1746e0efbd60ae3ab4fd65442247b2e26e56a642aaf